Cancer Immunotherapy Market Size, Share, Trends - Analysis Report
According to research report the Cancer Immunotherapy Market is projected to reach USD 119.39 Billion by 2021 from USD 61.97 Billion in 2016, at a CAGR of 14.0%.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=197577894
Market
growth factors such as increasing adoption of target therapy over
traditional therapy, emergence of biosimilars, increasing demand for
mAbs, high prevalence of cancer. Cancer immunotherapy drugs are designed
to alter or boost the body’s natural immune response to fight cancer
this market is research-driven with a high degree of dependence on the
discovery of molecules that can generate an immune response against
various indications.
Based on regions, the global Cancer
Immunotherapy market is segmented into North America, APAC, Europe and
the Rest of the World (RoW). North America is expected to account for
the largest share of the market during the forecast period. Growth in
this regional segment is driven by factors such as increase in patient
pool, and initiative taken by the government for the development of
Cancer Immunotherapy.
Speak To Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=197577894
In this report, the global cancer immunotherapy market has been segmented based on type, application, end user, and region.
On
the basis of type, the market has been segmented into monoclonal
antibodies, cancer vaccines, checkpoint inhibitors, and
immunomodulators. The monoclonal antibodies segment is expected to
account for the largest share of the market in 2016, while the
checkpoint inhibitors segment is projected to witness the highest CAGR
from 2016 to 2021. The high growth in this segment is primarily
attributed to the high success rate of these inhibitors.
On the
basis of applications, the global cancer immunotherapy market is
segmented into lung cancer, breast cancer, colorectal cancer, melanoma,
prostate cancer, head & neck cancer, and others. The lung cancer
segment is expected to grow at the highest CAGR during the forecast
period. The high growth in this segment can be attributed to the
increasing prevalence of this type of cancer and rising demand for
advanced treatment options.
Key players in the cancer
immunotherapy market include Amgen (U.S.), AstraZeneca (U.K.), F.
Hoffmann-La Roche AG (Switzerland), Bayer AG (Germany), Bristol-Myers
Squibb (U.S.), Eli Lilly and Company (U.S.), Janssen Global Services,
LLC (Belgium), Merck (U.S.), Novartis (Switzerland), and Pfizer (U.S.).
Get Report Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=197577894
Comments
Post a Comment